Diasorin S.p.a. · MIL:DIA
Diasorin — Investor Day
11 slides from Diasorin's investor day presentation
Slide 1: Markets and Sales
MARKETS AND SALES Chen Even Senior Corporate VP Commercial Operations
Slide 2: DiaSorin in the €7bn Immunoassays Segment
DIASORIN IN THE ¤ 7BN IMMUNOASSAYS SEGMENT OUT OF A WW IVD MARKET OF ¤ 33BN, DIASORIN MAIN FOCUS IS IMMUNOASSAY IMMUNO ASSAYS ¤ 7BN OUT OF A WW IMMUNOASSAY DRUG MONITORING OTHER MARKET OF ¤ 7BN, DIASORIN MAIN GI STOOL CLINICAL AREAS OF INTEREST ARE: TESTING 250 ALLERGY 300 ONCOLOGY 400 & ENDOCRINOLO
Slide 3: Infectious Disease market share and strategy
INFECTIOUS DISEASE (ex Heps & Retrovirus) MARKET MARKET PLAYERS NORTH WW: ¤ 850MLN MARKET SHARE AMERICA SIEMENS TRENDS LATAM DIASORIN: 10% 30% OTHERS ID growing WW following 250 10% demographics at 3-5% in ABBOTT: 25% the US and LatAm and >10% 150 BIOMÉRIEUX: 15% 10% in China ROCHE SIEMENS: 10% PRIC
Slide 4: Hepatitis & Retrovirus market share and strategy
HEPATITIS & RETROVIRUS MARKET MARKET PLAYERS WW: ¤ 1.5BN OTHERS ABBOTT USA LATAM MARKET SHARE WW ex US, ex JAPAN: DIASORIN 10% 5% 40% ¤ 750MLN 500 200 DIASORIN: 5% TRENDS ABBOTT: A 40% Growing volumes due to SIEMENS: 15% ROCHE 15% demographics, patients ROCHE: 15% access to testing and 350 urbanizat
Slide 5: GI Stool Testing market share and strategy
GI STOOL TESTING MARKET MARKET PLAYERS EUROPE MERIDIAN WW: ~ ¤ 300MLN MARKET SHARE ROW EUROPE: ¤ 90MLN TRENDS 90 MERIDIAN: 30% CAGR at +10-15% 60 30% Increasing incidence of C. OTHER SMALL-MEDIUM Difficile (hospital acquired PLAYERS: 70% infections) Low penetrated H. Pylori 150 Market size not attra
Slide 6: Oncology / Endocrinology market share and strategy
ONCOLOGY / ENDOCRINOLOGY MARKET MARKET PLAYERS EUROPE WW: ¤ 1.8BN MARKET SHARE APAC OTHERS TRENDS ROCHE ID increase in volume due to 350 DIASORIN: > 2% 18% 35% higher prevalence, population 700 ROCHE: 35% ageing and promotion of urban lifestyle SIEMENS: 25% 2% 250 2 50 ABBOTT: 20% OTHERS: ~ 18% 20%
Slide 7: Nucleic Acid Testing (NAT)
NUCLEIC ACID TESTING (NAT) MARKET MARKET PLAYERS WW: ¤ 3.4BN LATAM MARKET SHARE SIEMENS MENS APAC GEN TRENDS PROBE 9% Annual increase: +17% 450 250 ROCHE: 25% OTHERS 9% • Oncology: +34% QIAGEN: 15% 32% • Viral infection: +12% ABBOTT: 10% 1,500 ABBOTT 10% PRICING G GEN-PROBE: 9% Decrease 10% due to:
Slide 8: Geographical Expansion
GEOGRAPHICAL EXPANSION BRAZIL AUSTRIA CANADA AUSTRALIA INDIA CHINA CZECH REP. NETHERLANDS PURPOSE: penetrate ISRAEL IRELAND SOUTH AFRICA a fast growing MEXICO PORTUGAL market STRATEGY: JV with local distributors JAPAN PURPOSE: penetrate the richest IVD market STRATEGY: local distributor support or a
Slide 9: LIAISON XL, the New Front Line Analyzer
LIAISON XL, THE NEW FRONT LINE ANALYZER HIGH THROUGHPUT 180 TESTS/HOUR FULL LSN MENU + HIV AND HCV UP TO 25 REAGENTS ON BOARD AVAILABLE TO CONNECT WITH LAS CONSUMABLES TOUCH SCREEN LOADING VIDEO STARTER REAGENTS REAGENTS SAMPLES MICROPARTICLES LOADING SUSPENDING AREA CABINET A COMPACT AND EFFICIENT
Slide 10: From LIAISON to LIAISON XL
FROM LIAISON TO LIAISON XL 240 MAJOR COMPETITORS ARCHITECT 2000 200 CENTAUR XP UNICELDXI 600 VITROS 3600 160 COBAS E THROUGHPUT/H 120 MAJOR COMPETITORS 80 CENTAUR CP ARCHITECT 1000 ACCESS II 40 0 5 10 15 20 25 30 35 40 REAGENT CHANNELS FROM LIAISON, BENCH TOP SPECIALTY MARKET ANALYZER TO LIAISON XL,
Slide 11: LIAISON XL: Competitive Environment
LIAISON XL: COMPETITIVE ENVIRONMENT DIASORIN ROCHE BECKMAN ABBOTT SIEMENS ORTHO COBAS COULTER ARCHITECT CENTAUR VITROS E DXI 600 2000 XP 3600 THROUGHPUT 120 180 170 200 200 240 180 TOTAL MENU 92 94 73 57 50 60 50 MENU OF “SPECIALTIES” ++++ ++++ ++ + + + + TECHNOLOGY CLIA CLIA ECLIA CLIA CMIA CLIA CL